How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,084 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Contraceptive use among lactating women in Ganta-Afeshum District, Eastern Tigray, Northern Ethiopia, 2015: a cross sectional study. (PubMed)

delivery was 96.5%. The mode of delivery of the participants was spontaneous, instrumental and caesarean section, 95.5%, 2.0%, and 2.5%, respectively. The magnitude of modern contraceptive (MC) utilization was 68.1% (95% CI: 64.4-71.8). The contraceptive method mix was dominated by Depo-Provera (58.8%) followed by implants (31.8%). Almost all the study participants had at least one antenatal care (ANC) visit (99.7%) during the pregnancy of their index child. Participants who had radio and those who

Full Text available with Trip Pro

2017 BMC Pregnancy and Childbirth

142. Greater involvement of HIV-infected peer-mothers in provision of reproductive health services as "family planning champions" increases referrals and uptake of family planning among HIV-infected mothers. (PubMed)

points. FP uptake among mothers in need increased by over 31 percentage points (P < 0.001) from 47.2 to 78.5 percentage points during the intervention. There was a positive non-significant change in the weekly trend of referral β3 = 2.9 percentage points (P = 0.077) and uptake β3 = 1.9 percentage points (P = 0.176) during the intervention as compared to the pre-intervention but this was reversed during the post intervention. Over 57% (2494) mothers took up Depo-Provera injectable-FP method during

Full Text available with Trip Pro

2017 BMC health services research

143. His power over her was cultural. How could I do the right thing?

and about the times when she was most likely to get pregnant. In a bizarre reversal of the usual fertility counseling, I explained how to use cervical mucus and timing to try to avoid conception. Then I suggested that she have a Depo-Provera shot, which would prevent pregnancy for three months. “Yes,” she said. “But no one can know.” “It might show up on the insurance bill,” I warned. She felt that she couldn’t risk it. Finally, Eman told me to take out the IUD. “That is what I came here for, so I (...) will do it.” We decided to tell Ali that Depo-Provera was the birth-control method she’d chosen. Secretly I hoped that the shot’s effects might last for up to a year, as they sometimes do. I invited Ali and the children back into the room. “Three months?” Ali said. “No, we don’t need that. She can just take a pill for a week or two, while we decide.” “It sounds like you’ve already decided,” I wanted to say — but I bit my tongue. Alienating Ali wouldn’t help Eman, especially since I was still hoping

2017 KevinMD blog

144. Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days) or other substance abuse (use within the last 6 months of controlled substances other than marijuana without a prescription) Unwilling or unable or to avoid use of drugs that may dull

2017 Clinical Trials

145. Carbohydrate Availability and microRNA Expression

aerobic and/or resistance exercise Refrain from taking any NSAIDS (i.e., aspirin, Advil®, Aleve®, Naprosyn®, or any aspirin-containing product for 10 days before and at least 5 days AFTER each muscle biopsy. (*Tylenol® or acetaminophen is ok to use if needed for discomfort) Refrain from the use of alcohol and nicotine for the duration of the study Females must be on contraception (e.g., oral birth control, NuvaRing®, Depo Provera®, etc.) Supervisor approved leave status for federal civilian employees

2017 Clinical Trials

146. Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

), and postcoital contraceptive methods) and hormone replacement therapy must have been discontinued at least 28 days prior to the first dose of palbociclib. Depo Provera must have been discontinued at least 6 months prior to the first dose of palbociclib. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing. History of sensitivity to heparin or heparin induced thrombocytopenia. History of human immunodeficiency virus (HIV), hepatitis B

2017 Clinical Trials

147. Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

sterilization oral contraceptives (consisting of an estrogen-progestin combination or progestin alone transdermally derived contraceptives (e.g., Ortho - Evra), depot injections (e.g., Depo-Provera) vagina contraceptive ring (e.g., Nucaring), contraceptive implants (e.g., Implanon, Norplant 2/Jadelle) an intrauterine device diaphragm plus condom (the only acceptable double barrier method) other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted Subject has had concomitant

2017 Clinical Trials

148. Menopause Effects on Vascular Function

using Depo-provera or an intra-uterine device (IUD) Pregnant, are planning on becoming pregnant, or are breast- feeding. History of stable or unstable angina Diabetes Neurological disease Lung disease Kidney or liver disease Cancer Hysterectomy Peripheral vascular disease History of blood clots Heart disease Fibroids High blood pressure Stroke Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2017 Clinical Trials

149. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

. Pregnancy and/ or Lactation: Women of childbearing potential will be required to have a negative urine pregnancy test and to use contraception measures during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Moderate anemia, defined as hemoglobin <10.9 in both men

2017 Clinical Trials

150. Directed Ablation of Uterine Fibroids Using a Noninvasive Approach

intracavitary) Patients with known endometrial hyperplasia. Patients planning or seeking additional therapies for the treatment of fibroids and/or abnormal uterine bleeding. Patients with other pelvic masses of unknown etiology. Patients who are postmenopausal. Patients with an active diagnosis of cancer of any type. Patients on hormone therapy such as Depo-Provera, Lupron, etc. Patients who within 6 months prior to enrollment had procedures or surgery for the fibroid(s) to be treated as part

2017 Clinical Trials

151. Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

) Exclusion Criteria: Has not reached menarche Menopause: natural or induced by surgical/medical treatment Pregnant or breasfeeding Female or her male partner refuses to use barrier method of birth control (for sexually active) Current use of any of the following contraceptives (copper IUD, oral combined, Progestin-only including but not limited to: Provera, Aygestin, Nexplanon, Implanon, Depo Provera, Mirena IUD) VWF:Ag or VWF:RCo <40% Diagnosis of a qualitative platelet disorder Personal history

2017 Clinical Trials

152. Safety, PK, and PD Study of IVRs Releasing TFV and LNG

had at least two spontaneous menses since pregnancy outcome Use of any hormonal contraceptive method in the last 3 months (oral, transdermal, transvaginal, implant, or hormonal intrauterine contraceptive device) Injection of Depo-Provera in the last 10 months Use of copper IUD Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study History of sensitivity/allergy to any component of the study products, topical anesthetic

2017 Clinical Trials

153. Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

, hysterectomy, removal of the uterus, bilateral oophorectomy, removal of both ovaries) at least 6 months before dosing) or one year post menopausal), abstinent or using adequate contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; diaphragm, cervical cap, or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) from 3 months prior to this study through 56 days after challenge A negative pregnancy test at the time of enrollment Free

2017 Clinical Trials

154. Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety in Patients With Hypoglycemia After Gastric Surgery

; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill/patch I vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide

2017 Clinical Trials

155. Maximizing Outcome of Multiple Sclerosis Transplantation

intercourse, (2) consistent use of birth control pills, (3) injectable birth control methods (Depo-provera, Norplant), (4) tubal sterilization or male partner who has undergone vasectomy, (5) placement of an intrauterine device (IUD), or (6) with every act of intercourse, use of diaphragm with contraceptive jelly and/or use of condom with contraceptive foam Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy Forced expiratory volume at one second (FEV1)/ forced

2017 Clinical Trials

156. Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

injections (e.g. Depo-provera), copper-banded intra-uterine devices, hormone-impregnated intra-uterine systems and vasectomised partners; all methods of contraception, with the exception of total abstinence, should be used in combination with the use of a condom by male sexual partners). Known hypersensitivity or any contraindications to the trial drugs, including nab-paclitaxel/nintedanib, to their excipients or to contrast media or other ingredients including peanuts and soya. Patients unable to comply

2017 Clinical Trials

157. The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

opinion, may interfere with study participation. Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant(R), Depo-Provera(R) double barrier methods (e.g., condom and spermacide) and abstinence. Subjects must provide written informed consent. Willingness to comply with the study design and procedures. Subjects who agree to sign

2017 Clinical Trials

158. Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

contraception (eg, abstinence, double barrier method, oral/implantable/transdermal contraception, Depo-Provera, intrauterine device); a woman is of CBP unless she is premenarchal, is at least 2 years postmenopausal, is without a uterus and/or both ovaries, has had a bilateral tubal ligation, or has undergone the Essure procedure with confirmation of tubal blockage. [Note: If a female is identified as less than 2 years postmenopausal, a serum follicle-stimulating hormone (FSH) determination will be performed

2017 Clinical Trials

159. Hypoglycemia and the Gut Microbiome

pint of whole blood) within the past 2 months; Active alcohol abuse or substance abuse; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant

2017 Clinical Trials

160. Modifiers of Tenofovir in the Female Genital Tract

): University of Minnesota - Clinical and Translational Science Institute Study Details Study Description Go to Brief Summary: Two-armed, single visit, pharmacokinetic study to compare tenofovir diphosphate concentrations in cervical tissues of women on Depo-Provera contraception vs non-hormonal contraception. Condition or disease Intervention/treatment HIV/AIDS Contraception Drug: Tenofovir Disoproxil Fumarate Drug: Depo-Provera Study Design Go to Layout table for study information Study Type (...) : Observational Actual Enrollment : 50 participants Observational Model: Case-Control Time Perspective: Cross-Sectional Official Title: Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera Actual Study Start Date : November 17, 2017 Actual Primary Completion Date : March 29, 2018 Actual Study Completion Date : April 2, 2018 Resource links provided by the National Library of Medicine related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>